SRR1096851
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.379
- APICAL_SURFACE+0.370
- PANCREAS_BETA_CELLS+0.329
- TNFA_SIGNALING_VIA_NFKB+0.286
- HEDGEHOG_SIGNALING+0.268
- CHOLESTEROL_HOMEOSTASIS+0.249
- SPERMATOGENESIS+0.249
- MYOGENESIS+0.245
- ANGIOGENESIS+0.238
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.238
Top 10 suppressed
- MYC_TARGETS_V1-0.482
- G2M_CHECKPOINT-0.472
- E2F_TARGETS-0.467
- INTERFERON_ALPHA_RESPONSE-0.430
- DNA_REPAIR-0.406
- MYC_TARGETS_V2-0.383
- MITOTIC_SPINDLE-0.331
- UNFOLDED_PROTEIN_RESPONSE-0.325
- INTERFERON_GAMMA_RESPONSE-0.309
- PROTEIN_SECRETION-0.305
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR660330 | GTEX | — | 0.933 |
| 2 | SRR1418818 | GTEX | — | 0.921 |
| 3 | SRR1083100 | GTEX | — | 0.900 |
| 4 | SRR1409305 | GTEX | — | 0.894 |
| 5 | BS_5K3R0F5D | Ganglioglioma | — | 0.893 |
| 6 | SRR656564 | GTEX | — | 0.892 |
| 7 | MNG113 | — | — | 0.887 |
| 8 | SRR603333 | GTEX | — | 0.881 |
| 9 | SRR1353221 | GTEX | — | 0.881 |
| 10 | MNG188 | — | — | 0.878 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.379 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.370 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.329 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.286 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.268 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.249 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.249 | Inavolisib | — uncovered |
| MYOGENESIS | 0.245 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.238 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.238 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.217 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.139 | Inavolisib | — uncovered |
| COAGULATION | 0.129 | Binimetinib | — uncovered |
| HYPOXIA | 0.129 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.107 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.106 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.097 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.034 | Inavolisib | — uncovered |